Overview

A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Status:
Not yet recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Treatments:

Carboplatin